Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Depression and/or Anxiety in the Mild-to...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to evaluate the feasibility, acceptability, and preliminary effectiveness of the SanaMente peer-led mental health and lifestyle program for rural Latino/a adults with chronic medical conditions and mental health concerns. The main questions it aims to answer are: * Is the SanaMente program feasible and acceptable for rural Latino/a adults with chronic medical conditions and mental health concerns? * Does participation in the SanaMente program improve mental health outcomes (depression, anxiety, and stress), healthy lifestyle behaviors (sleep, physical activity, and nutrition), and overall well-being? This is a single-arm pilot study without comparison group. Participants will: * Participate in the 6-8 week SanaMente peer-led group program. * Complete surveys at baseline, mid-program, and post-program assessing mental health, lifestyle behaviors, overall well-being, and program satisfaction. * Complete an exit survey and have the option to participate in a focus group to provide feedback on the program's usability, acceptability, perceived impact, and suggestions for improvement.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: SanaMente — SanaMente is a culturally responsive, peer-led behavioral program designed to support mental health and promote healthy lifestyle behaviors among rural Latino/a adults with chronic medical conditions and mental health concerns. The program is delivered by trained bilingual peer mentors in small group sessions over 6-8 weeks and integrates evidence-based strategies to improve depression, anxiety, stress, sleep, physical activity, nutrition, and overall well-being. The intervention emphasizes culturally relevant content, peer support, and skill-building to enhance self-management and emotional wellness.

Primary Outcomes

  • Depression as assessed by the Patient Health Questionnaire-9 (PHQ-9) (Baseline, Mid-Program (Week 3-4), and Post-Program (Week 6-8))
  • Anxiety as assessed by the Generalized Anxiety Disorder-7 (GAD-7) (Baseline, Mid-Program (Week 3-4), and Post-Program (Week 6-8))
  • Body Weight (Baseline and Post-Program (week6-8))
  • Systolic Blood Pressure (Changes from Baseline and Post-Program (week6-8) will be evaluated)
  • Diastolic Blood Pressure (Changes from Baseline and Post-Program (week6-8) will be evaluated)
  • Resting Heart Rate (Changes from Baseline and Post-Program (week6-8) will be evaluated)
  • Glycemic control as assessed by Hemoglobin A1c (HbA1c) (Changes from Baseline and Post-Program (week6-8) will be evaluated)
  • Total Cholesterol (Changes from baseline to post-program (week 6-8) will be evaluated.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-06
Completion: 2026-12-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Colorado, Boulder
Collaborators: La Clinica del Pueblo
Principal Investigators:
  • Anahi Collado, PhD (PRINCIPAL_INVESTIGATOR) - University of Colorado, Boulder
Contact Information
Study Contact:
Antonella Onofrietti Magrassi, PhD
15417807253
antonella.onofrietti@colorado.edu
Anahi Collado, PhD
3052835243
anahi.collado@colorado.edu
Jenny Lang, Clinical Director, FNP
9706183841
jenny@peoplesclinic.care
La Clinica del Pueblo
Interventions
  • Behavioral: SanaMente — SanaMente is a culturally responsive, peer-led behavioral program designed to support mental health and promote healthy lifestyle behaviors among rural Latino/a adults with chronic medical conditions and mental health concerns. The program is delivered by trained bilingual peer mentors in small group sessions over 6-8 weeks and integrates evidence-based strategies to improve depression, anxiety, stress, sleep, physical activity, nutrition, and overall well-being. The intervention emphasizes culturally relevant content, peer support, and skill-building to enhance self-management and emotional wellness.
Study Locations (1 sites)
La Clinica del Pueblo, Carbondale, Colorado 81623 United States
Eligibility Criteria
Inclusion Criteria: * Adults aged 18 years or older. * Identify as Hispanic/Latino/a. * Patients of La Clínica del Pueblo in Carbondale, Colorado. * Spanish-speaking (bilingual Spanish-English speakers are eligible). * Interest in improving your physical and emotional well-being. * Are currently managing or are at risk for chronic medical or metabolic conditions (e.g., diabetes, cardiovascular disease, liver, or kidney conditions), but a diagnosis is not required. * Experiencing or at risk for stress, low mood, or anxiety (formal diagnosis not required) * Willingness and ability to participate in the SanaMente program. * Willing to provide a release of information authorizing study staff to communicate with La Clínica del Pueblo in the event that a participant endorses suicidality or if it becomes necessary to share relevant medical information to ensure participant safety and appropriate care. Exclusion Criteria: * Individuals who are unable to provide informed consent. * Individuals who are unwilling or unable to participate in the group-based or one-to-one SanaMente sessions.
Conditions Kidney Transplant; Complications, Frailt...
Phase Not Applicable
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

This observational study aims to analyze the results of comprehensive geriatric assessment and to monitor the development of functional status in geriatric kidney transplant candidates and recipients.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Procedure: Functional geriatric assessment — Examination of physical and mental status using standardized tests.

Primary Outcomes

  • Frailty syndrome (Fried frailty phenotype) (2020-2040)
  • Acceptance for kidney transplantation (Number of patients listed for kidney transplantation and number of transplanted patients) (2020-2040)
  • Outcomes of kidney transplantation (Graft and patient surival, number of patients with related adverse events) (2020-2040)
  • Functional status evaluated by comprehensive geriatric assessment (2020-2040)
  • Depressive syndrome (amount of depressive symptoms measured by GDS scale) (2020-2040)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2020-01-02
Completion: 2040-01-02
Eligibility
Age: 60 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Institute for Clinical and Experimental Medicine
Principal Investigators:
  • Silvie Rajnochova Bloudickova, MD,PhD (STUDY_DIRECTOR) - Department of Nephrology, Institute for Clinical and Experimental Medicine
  • Hana Vankova, MD,PhD (PRINCIPAL_INVESTIGATOR) - Charles University, Czech Republic
Contact Information
Study Contact:
Silvie Rajnochova Bloudickova, MD,PhD
261362223
sibl@ikem.cz
Hana Vankova, MD,PhD
261362223
ha.van@seznam.cz
Silvie Rajnochova Bloudickova, MD, PhD
+420 26136 2223
sibl@ikem.cz
Department of Nephrology Transplant Centre IKEM
Interventions
  • Procedure: Functional geriatric assessment — Examination of physical and mental status using standardized tests.
Study Locations (1 sites)
Department of Nephrology Transplant Centre IKEM, Prague, 140 21 Czechia
Eligibility Criteria
Inclusion Criteria: * kidney transplant candidates aged 60+ years * kidney transplant recipients aged 60+ years Exclusion Criteria: * kidney transplant candidates aged below 60 years * kidney transplant recipients aged below 60 years
Conditions Rare Genetic Disorders, Quality of Life,...
Phase Not Applicable
Enrollment 45
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to examine the psychological status and quality of life of families with children who have rare genetic disorders. The focus of the study is to understand how the child's level of functional independence relates to the well-being of the family. Functional independence will be assessed using standardized tools, and parental psychological status and quality of life will be evaluated with validated questionnaires. The information gathered from this study may help improve the understanding of how rare genetic disorders affect family dynamics and daily functioning. The results may guide health care professionals in planning family-centered physiotherapy, psychological support, and care programs.

Design

Study type: Observational Observational model: Other Time perspective: Prospective

Primary Outcomes

  • Functional Independence Level of the Child (WeeFIM) (At baseline (study enrollment))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-10-25
Completion: 2026-03-15
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: true
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Bahçeşehir University
Principal Investigators:
  • Tuğçe Tahmaz, PhD (PRINCIPAL_INVESTIGATOR) - Bahçeşehir University
Contact Information
Study Contact:
Yağmur Erkan, PT
+90 506 940 0759
yagmurerkn@gmail.com
Tuğçe Tahmaz, PhD
+905330397791
tugcetahmaz@msn.com
Yağmur Erkan, PT
Bahcesehir University
Interventions
N/A
Study Locations (1 sites)
Bahcesehir University, Istanbul, 34053 Turkey (Türkiye)
Eligibility Criteria
Inclusion Criteria: * Caregivers of children aged 0-4 years diagnosed with a rare genetic disorder. * The child must have been receiving physiotherapy for at least 6 months. * Caregivers who voluntarily agree to participate and provide informed consent. * Caregivers who are able to read and understand Turkish to complete the questionnaires. Exclusion Criteria: * Caregivers who have cognitive or language limitations that prevent them from completing the questionnaires. * Caregivers who decline participation or submit incomplete questionnaire forms. * Children or caregivers with an additional medical or neurological condition that prevents participation in the study.
Conditions Depressive/Anxiety Symptoms, Depressive ...
Phase NA
Enrollment 216
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to find out whether a smartphone app can help reduce symptoms of depression by supporting healthy lifestyle changes and encouraging self-monitoring in adults who visit their general practitioner with symptoms of depression. The main questions this study aims to answer are: Does a personalized lifestyle intervention delivered through the app, in addition to regular care, reduce depression symptoms more effectively than regular care alone? Is this approach more cost-effective than regular care alone? Researchers will compare patients who use the app alongside their regular care to patients who receive regular care without the app, to see whether the app leads to better outcomes. Participants who use the app will: Complete a lifestyle questionnaire focused on six themes: mental wellbeing, use of harmful substances, social relationships, healthy eating, sleep, and physical activity. Set personal goals based on their results and receive tailored lifestyle advice. Track their depression symptoms regularly within the app to support ongoing care. Have follow-up conversations with their general practitioner or mental health nurse to discuss their progress. Fill out questionnaires about their symptoms and experiences during the study.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Device: Personalized Lifestyle Intervention — The personalized lifestyle intervention (PLI) consists of the combined use of the Patient Journey App (PJA) alongside care provided by the general practitioner or mental health nurse. The Patient Journey App integrates four digital health tools within a single smartphone application: 1. A brief lifestyle questionnaire covering six key areas: mental wellbeing, minimizing harmful substance use, social relationships, healthy eating, sleep, and physical activity. 2. A personalized summary of the questionnaire results, which supports the formulation of two personal lifestyle goals. 3. Tailored information and advice about lifestyle, including suggested interventions, based on the patient's personal goals. 4. Monitoring of depression symptoms over time to support measurement-based care. General practitioners and mental health nurses will have access to the app to monitor patient progress and outcomes.

Primary Outcomes

  • Cost-effectiveness of the Personalized Lifestyle Intervention at 6 months after baseline (Baseline to 6 months)
  • Change in quality of life using the EQ-5D-5L (Baseline to 6 months)
  • Change from baseline in the mean depression severity score measured by the PHQ-9 at 6 months after baseline (Baseline to 6 months.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-06-17
Completion: 2027-02
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 216 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Radboud University Medical Center
Collaborators: Ixta Noa, Hogeschool van Arnhem en Nijmegen (HAN), Pro Persona Mental Health Care Foundation, Amsterdam UMC, Interactive Studios, University Medical Center Groningen
Contact Information
Study Contact:
Eline Jagtenberg
0652902132
eline.jagtenberg@radboudumc.nl
Suzanne Ligthart
suzanne.ligthart@radboudumc.nl
Eline Jagtenberg
0652902132
eline.jagtenberg@radboudumc.nl
Radboudumc
Interventions
  • Device: Personalized Lifestyle Intervention — The personalized lifestyle intervention (PLI) consists of the combined use of the Patient Journey App (PJA) alongside care provided by the general practitioner or mental health nurse. The Patient Journey App integrates four digital health tools within a single smartphone application: 1. A brief lifestyle questionnaire covering six key areas: mental wellbeing, minimizing harmful substance use, social relationships, healthy eating, sleep, and physical activity. 2. A personalized summary of the questionnaire results, which supports the formulation of two personal lifestyle goals. 3. Tailored information and advice about lifestyle, including suggested interventions, based on the patient's personal goals. 4. Monitoring of depression symptoms over time to support measurement-based care. General practitioners and mental health nurses will have access to the app to monitor patient progress and outcomes.
Study Locations (3 sites)
Radboudumc, Nijmegen, Gelderland 6525GA Netherlands
Amsterdam UMC, Amsterdam, North Holland 1105 AZ Netherlands
UMC Groningen, Groningen, Provincie Groningen 9713 GZ Netherlands
Eligibility Criteria
Inclusion Criteria: * Currently experiencing an episode of symptoms of depression and receiving treatment for this episode from their GP or GP-MHW for less than six months * Have a smartphone * Be proficient in Dutch Exclusion Criteria: * Severe mental illness (such as psychosis or bipolar disorder) * Severe alcohol or drug addiction requiring specialized secondary care * High suicide risk * moderate to severe cognitive impairment (as determined by the GP) Patients who visit their GP for depressive symptoms but with a PHQ-9 of \<5 at baseline are allowed to use the PLI, but will not be included in the primary analysis.
Conditions Inflammatory Bowel Diseases
Phase NA
Enrollment 88
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

For the first time, this study developed an anti-inflammatory diet (AID) recipe suitable for Inflammatory bowel disease(IBD) patients and developed an AID application program to verify the intervention effect of AID on IBD patients, which not only promoted the application of AID in IBD patients and promoted the promotion of AID model, but also provided new ideas for the prevention and treatment strategies for IBD patients.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Double

Interventions / Regimen

  • Behavioral: Anti-inflammatory diet group — Patients in the intervention group were given AID knowledge education, and patients were asked to pay attention to the "anti-inflammatory diet" wechat mini program developed by the researchers to teach patients how to use it, including the selection of anti-inflammatory diet, unsuitable anti-inflammatory diet, diet alarm clock, diet notes and other related functions. The missionary patients insisted on AID until reexamination 8 weeks later.

Primary Outcomes

  • C-reactive protein (8 weeks after intervention)
  • Erythrocyte sedimentation rate (ESR) (8 weeks after intervention)
  • Leukocyte (8 weeks after intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-01
Completion: 2025-12-31
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: true
Enrollment: 88 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Principal Investigators:
  • Xia Qian, BA (PRINCIPAL_INVESTIGATOR) - The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Contact Information
Study Contact:
Xia Qian, BA
15968110117
1632936247@qq.com
Lili Yang, PhD
13958131637
3200006@zju.edu.cn
Xia Qian, BA
15968110117
1632936247@qq.com
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Interventions
  • Behavioral: Anti-inflammatory diet group — Patients in the intervention group were given AID knowledge education, and patients were asked to pay attention to the "anti-inflammatory diet" wechat mini program developed by the researchers to teach patients how to use it, including the selection of anti-inflammatory diet, unsuitable anti-inflammatory diet, diet alarm clock, diet notes and other related functions. The missionary patients insisted on AID until reexamination 8 weeks later.
Study Locations (1 sites)
The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu, Zhejiang 322000 China
Eligibility Criteria
Inclusion Criteria: 1. Diagnosis of inflammatory bowel disease, the diagnostic criteria refer to the 2018 revised Consensus opinion on the diagnosis and treatment of inflammatory bowel disease; 2. The patient has clear consciousness and certain understanding, language expression and writing ability; 3. Patients participated in this study knowingly and voluntarily; 4. At least 18 years old. Exclusion Criteria: 1. cognitive impairment, mental illness, accompanied by mental disorders; 2. Alcohol and drug abusers. 3. The patient could not participate in the researcher due to the deterioration of the condition; 4. Patients who voluntarily quit due to other reasons; 5. Those who did not complete the assessment scale during the experiment.
Conditions Bipolar Disorder
Phase PHASE2
Enrollment 25
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

Preliminary data have suggested that cannabidiol (CBD) may have a number of clinical benefits, including anti-anxiety and antidepressant properties. This study is a pilot open-label clinical trial assessing a custom-formulated high-CBD product over the course of 4 weeks in patients with bipolar disorder who experience anxiety.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Cannabidiol — Custom formulation of a hemp-derived, high-CBD product that contains no THC.

Primary Outcomes

  • Change in self-reported ratings of anxiety on the Beck Anxiety Inventory (BAI) (4 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-06-01
Completion: 2026-12
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 25 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mclean Hospital
Contact Information
Study Contact:
Rosemary Smith, B.S.
617-855-3338
CBDstudy@mclean.harvard.edu
Rosemary Smith, B.S.
617-855-3338
CBDstudy@mclean.harvard.edu
McLean Hospital
Interventions
  • Drug: Cannabidiol — Custom formulation of a hemp-derived, high-CBD product that contains no THC.
Study Locations (1 sites)
McLean Hospital, Belmont, Massachusetts 02478 United States
Eligibility Criteria
Inclusion Criteria: * Provides informed consent * Between the ages of 18-65 * Fluent in English * Meets DSM-5 criteria for bipolar disorder (type I or II) * Experiences at least moderate levels of anxiety (as evidenced by self-reported rating scales) * On a stable pharmacotherapeutic regimen Exclusion Criteria: * Not fluent in English * Estimated IQ \<75 * Current substance use disorder, current eating disorder, current or past psychotic disorder (e.g. schizophrenia, schizoaffective disorder) * Endorsement of suicidality * Experiencing acute manic episode * Experiencing acute depressive episode * History of head injury/loss of consciousness \>5 minutes * Current regular use of cannabinoid products * Pregnant or breastfeeding * Presence of serious medical illness or neurological disorder * Allergy to palm oil * Current use of valproate or divalproex; other concomitant medications may result in exclusion on a case-by-case basis * Currently enrolled in another clinical trial that involves a treatment * Elevated LFTs at screening visit

Brain Connectivity in Depression

NCT03276793
Recruiting
Conditions Depression
Phase NA
Enrollment 260
Locations 4 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

This study originally included 140 subjects with medication-refractory depression undergoing 10 Hz transcranial magnetic stimulation (10Hz-TMS) to the left dorsal lateral prefrontal cortex (DLPFC), with the goal of having 60 completers with good quality data. Subjects were recruited from the TMS clinics at Beth Israel Deaconess Medical Center, Brigham \& Women's Hospital, and Butler Hospital. Subjects underwent an hour-long MRI scanning session, an optional DNA-sample collection, up to three 20 minute neuronavigation sessions for marking the site of TMS stimulation, questionnaires, and a behavioral testing battery before and after their TMS treatment course. The task battery included the Emotion Conflict Resolution (ECR) task, Multi-Source Interference Task (MSIT), War Game (Gambling) task, and Associative Learning with Reversal task. Subjects' scores on the Quick Inventory of Depressive Symptomatology (QIDS) and Beck Depression Inventory (BDI) were assessed before and after the TMS course. MRI data was utilized to identify brain regions whose connectivity to the stimulation site co-varies with the aforementioned measures of symptom improvement. This was the only study group until August 30, 2022, and the primary outcome was analyzed for the 10Hz-TMS group. Due to changes in clinical standard of care from 10Hz-TMS to a newer version of TMS termed intermittent theta burst (iTBS), in September 2022 a second group was added to include patients receiving this new form of TMS. This second group included another 100 patients with medication-refractory depression undergoing iTBS to the left dorsal lateral prefrontal cortex (DLPFC), with the intent to have 80 completers. Massachusetts General Hospital was added as a data collection site in lieu of Butler Hospital. Subjects will undergo an hour-long MRI scanning session, up to three 20 minute neuronavigation sessions for marking the site of TMS stimulation, questionnaires, and a behavioral testing battery before and after their TMS treatment course. The task battery will included the Emotion Conflict Resolution (ECR) task, Multi-Source Interference Task (MSIT), Penn Emotion Recognition Test, the Suicide/Death Implicit Association Test, and Associative Learning with Reversal task. Subjects' scores on the Beck Depression Inventory (BDI) were assessed before and after the TMS course. MRI data will be utilized to identify brain regions whose connectivity to the stimulation site co-varies with the aforementioned measures of symptom improvement. Due to a higher dropout rate than anticipated, in March of 2025 an amendment was added to include an additional 20 subjects in the second group's enrollment goal to increase the likelihood of achieving 80 completers.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Basic Science Masking/blinding: None

Interventions / Regimen

  • Other: MRI scan — Patients will undergo an MRI scan
  • Behavioral: Behavioral testing — Patients will complete a series of cognitive tasks

Primary Outcomes

  • Prediction of repetitive Transcranial Magnetic Stimulation (rTMS) clinical response (1 year after study completion)
  • Prediction of intermittent theta burst stimulation (iTBS) clinical response (1 year after study completion)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2018-04-03
Completion: 2027-10-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 260 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Brigham and Women's Hospital
Collaborators: Butler Hospital, Massachusetts General Hospital, National Institute of Mental Health (NIMH)
Contact Information
Study Contact:
David Lawson, BA
617-732-6658
bwh_fdctrial@mgb.org
Emma Jones, BS
bwh_fdctrial@mgb.org
Michael D Fox, MD, PhD
617-732-7432
bwh_fdctrial@mgb.org
Brigham and Women's Hospital
Interventions
  • Other: MRI scan — Patients will undergo an MRI scan
  • Behavioral: Behavioral testing — Patients will complete a series of cognitive tasks
Study Locations (4 sites)
Brigham and Women's Hospital, Boston, Massachusetts 02115 United States
Massachusetts General Hospital, Boston, Massachusetts 02129 United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215 United States
Butler Hospital, Providence, Rhode Island 02906 United States
Eligibility Criteria
Inclusion Criteria: 1. Male or female 2. Aged 18 or older 3. Have previously received or will once daily TMS treatment to the left dorsolateral prefrontal cortex at the Center for Brain Circuit Therapeutics at Brigham and Women's Hospital, or at Massachusetts General Hospital for treatment of medication resistant depression Exclusion Criteria: 1. Presence of a significant neurologic disorder (i.e. Parkinson's Disease, stroke, Alzheimer's Disease, tumor, multiple sclerosis, epilepsy) or other significant active medical problems which may impact treatment or safety. Of note, many of these are also contraindications to receiving TMS and these patients would not be enrolled in the clinical treatment program. Because these diagnoses, their significance, and the extent to which they are an active issue can be subjective, each of these exclusions (1-3) will be reviewed by the PI or study physician 2. Lack of response to an adequate trial of electroconvulsive therapy (ECT) or any ECT in the preceding 3 months 3. Prior adequate trial of TMS treatment in the last 12 months 4. Positive MRI screen that would preclude the subject from undergoing magnetic resonance imaging. These include, but are not limited to any of the following: 1. Known metal in the head (such as a surgical aneurysm clip), or a history of prior neurosurgical procedures 2. Ferromagnetic bioimplants activated by any electronic, mechanical or magnetic means such as: cochlear implants, pacemakers, medication pumps, vagal stimulators, deep brain stimulators, neurostimulators, biostimulators, or ventriculo-peritoneal shunts 3. Subjects who have or might have bullet fragments or other metal fragments (veterans or workers exposed to metal in their work environment) 4. Subjects with metallic paint (e.g. color contact lenses, tattoos, metallic eyeliner) 5. Subjects expressing significant anxiety or claustrophobia about being in the magnet. 5. Subjects that cannot adhere to the experimental protocol for any reason.
Conditions MDD
Phase PHASE2
Enrollment 400
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

This multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding Phase II clinical trial aimed to determine the optimal dose of LV232 capsules for treating MDD, evaluate preliminary efficacy and safety, and provide a basis for Phase III trial design and dosing regimen determination.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Drug: LV232 40mg — LV232 capsules 2 capsules (20 mg/capsule) + LV232 capsule placebo 1 capsule + escitalopram oxalate tablet placebo 1 tablet
  • Drug: LV232 60mg — LV232 capsules 3 capsules (20 mg/capsule) + escitalopram oxalate tablet placebo 1 tablet
  • Drug: Escitalopram — LV232 capsule placebo 3 capsule + escitalopram oxalate tablet 1 tablet
  • Drug: Placebo — LV232 capsule placebo 3 capsule + escitalopram oxalate tablet placebo 1 tablet

Primary Outcomes

  • Change from baseline in Montgomery Asperger Depression Scale (MADRS) score at the end of treatment (week 8) (Baseline and week 8)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-04-03
Completion: 2027-12-20
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vigonvita Life Sciences
Principal Investigators:
  • Li Huafang (PRINCIPAL_INVESTIGATOR) - Shanghai Mental Health Center
Contact Information
Study Contact:
Duan Huaqing
+86-18061926005
huaqing.duan@vigonvita.cn
Shen yi feng
021-34773308
Shanghai Mental Health Center Ethics Committee
Interventions
  • Drug: LV232 40mg — LV232 capsules 2 capsules (20 mg/capsule) + LV232 capsule placebo 1 capsule + escitalopram oxalate tablet placebo 1 tablet
  • Drug: LV232 60mg — LV232 capsules 3 capsules (20 mg/capsule) + escitalopram oxalate tablet placebo 1 tablet
  • Drug: Escitalopram — LV232 capsule placebo 3 capsule + escitalopram oxalate tablet 1 tablet
  • Drug: Placebo — LV232 capsule placebo 3 capsule + escitalopram oxalate tablet placebo 1 tablet
Study Locations (1 sites)
Shanghai Mental Health Center Ethics Committee, Shanghai, China
Eligibility Criteria
Inclusion Criteria: 1. Fully understand the purpose, content, and potential adverse reactions of this trial, voluntarily participate in the clinical trial and sign a written informed consent form, able to complete the entire trial process as required and comply with the trial regulations; 2. Gender unrestricted, at screening: 18 years old ≤ age ≤ 65 years old; 3. Meet the DSM-5 (Diagnostic and Statistical Manual of Mental Disorders, 5th Edition) diagnostic criteria for depression according to the Mini International Neuropsychiatric Interview (M.I.N.I. 7.0.2), currently experiencing a single or multiple episodes; 4. For first-episode patients, the duration of the current depressive episode must be ≥3 months; for recurrent patients, the duration of the current depressive episode must be ≥1 month (each month is counted as 30 days, the same applies below); 5. During the screening and baseline periods, the total score on the Montgomery-Asberg Depression Rating Scale (MADRS) must be ≥26, and the Clinical Global Impression-Severity (CGI-S) score must be ≥4; 6. At screening and baseline visits, the score on the first item (depressed mood) of the HAMD-17 scale must be ≥2; 7. Female or male subjects of childbearing potential agree and commit to using effective contraception from the signing of the informed consent form until 3 months after the last administration of the trial drug. Exclusion Criteria: 1. Treatment-resistant depression (failure to respond to an adequate dose and duration of treatment, at least 8 weeks, with two antidepressants of different mechanisms) or failure to respond to an adequate dose and duration of treatment with escitalopram oxalate; 2. Meeting the diagnostic criteria for other mental disorders as per DSM-5 (such as schizophrenia spectrum and other psychotic disorders, bipolar and related disorders, generalized anxiety disorder, obsessive-compulsive and related disorders, somatic symptom and related disorders, etc.); 3. Meeting the DSM-5 criteria for substance use disorder; 4. Organic mental disorders, such as depression caused by hypothyroidism; 5. Depression induced by psychoactive substances or non-addictive substances; 6. Presence of depressive symptoms due to other diseases or other types of mental disorders; 7. A reduction of ≥25% in the MADRS score at baseline compared to the screening period; 8. Assessed by the Columbia Suicide Severity Rating Scale (C-SSRS) and judged by the investigator to be at risk of suicide, or having suicidal behavior within the 6 months prior to screening; 9. Presence of severe physical illnesses deemed by the investigator as grounds for exclusion, such as uncontrolled hypertension or severe unstable cardiovascular diseases, severe liver diseases, kidney diseases, blood diseases, endocrine diseases, neurological diseases, etc.; 10. Diseases affecting oral drug absorption, such as active bowel disease, partial or complete intestinal obstruction, chronic diarrhea, etc.; 11. Active malignancy or a history of malignancy within 5 years prior to screening (except for completely resected and cured squamous cell carcinoma, cervical carcinoma in situ, etc.); 12. History of increased intraocular pressure or narrow-angle glaucoma; 13. Individuals with allergic constitution, such as those allergic to two or more drugs or known to be allergic to escitalopram oxalate; 14. Use of drugs that alter the activity of liver enzymes (CYP2C19 and CYP2D6) within 4 weeks (or 5 half-lives, whichever is longer) prior to randomization (see Appendix 2); 15. Previous treatment with vagus nerve stimulation (VNS) and deep brain stimulation (DBS), or modified electroconvulsive therapy (MECT) within 3 months prior to randomization, or systematic psychotherapy (interpersonal therapy, dynamic therapy, cognitive behavioral therapy), transcranial magnetic stimulation (TMS), and light therapy within 1 month prior to randomization, or judged by the investigator to currently require such treatments; 16. Systematic antidepressant treatment within 2 weeks prior to randomization (not less than 30 days for fluoxetine), or discontinuation of psychotropic drugs for less than 5 half-lives prior to randomization (except for stable doses of sleep aids received within 4 weeks prior to randomization, including benzodiazepines (limited to estazolam, alprazolam, and oxazepam) and non-benzodiazepines); 17. Use of monoamine oxidase inhibitors such as phenelzine, isocarboxazid, tranylcypromine, etc., and linezolid, methylene blue, etc., within 2 weeks prior to randomization; 18. Second or third-degree atrioventricular block, long QT syndrome, or QTcF \> 450 ms (male)/460 ms (female) on 12-lead ECG at screening; 19. Discontinuation of drugs that prolong the QT interval (such as levofloxacin, fluconazole, ondansetron, amiodarone, metronidazole, erythromycin, and haloperidol, etc.) or drugs that may cause QT interval prolongation and induce torsade de pointes (TdP) for less than 5 half-lives at randomization; 20. ALT or AST above 2 times the upper limit of normal; creatinine above 1.5 times the upper limit of normal; 2 or more abnormal indicators in thyroid function tests (TSH, FT3, FT4, TT3, or TT4 below 0.9 times the lower limit of normal or above 1.1 times the upper limit of normal) at screening; 21. Positive for Treponema pallidum antibody and HIV antibody at screening; 22. Substance abuse (including alcohol, drugs, and other psychoactive substances) within 3 months prior to screening; 23. Female subjects who are breastfeeding or have a positive pregnancy test at screening or during the trial; 24. Participation in any interventional clinical trial and use of investigational drugs or medical devices within 3 months prior to screening, or currently participating in other clinical trials; 25. Other factors deemed by the investigator as unsuitable for participation in the trial.

Bright Light Therapy for OSA

NCT05917119
Recruiting
Conditions Obstructive Sleep Apnea
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

Persistent daytime symptoms of sleepiness in individuals with obstructive sleep apnea (OSA) who are using Continuous Positive Airway Pressure (CPAP) are associated with adverse long term medical and functional outcomes. Supplementary exposure to bright light has beneficial effects on sleep quality and daytime vigilance in healthy individuals and it has been increasingly applied in a variety of sleep and neuropsychiatric conditions. This study will explore the role of Bright Light Therapy (BLT), a well-established non-pharmacological intervention for circadian disturbances, for the treatment of residual daytime symptoms of OSA which do not respond to CPAP. BLT will be delivered via therapy glasses in a cross-over design, where each participant will be exposed to active treatment and sham treatment (4 weeks in each arm) in a randomized order. The hypothesis is that participants will demonstrate improvements in the variables of interest during the four-week active treatment portion of the eight-week crossover study, compared to the four-week sham treatment portion.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: Single

Interventions / Regimen

  • Other: BLT — Bright light therapy delivered via glasses
  • Other: s-BLT — sham delivered with bright light therapy glasses to which a neutral density filter has been applied

Primary Outcomes

  • Change in Epworth sleepiness scale (baseline, week 4 (end of treatment 1), week 8 (end of wash out), week 12 (end of treatment 2))
  • Change in QIDS score (baseline, week 4 (end of treatment 1), week 8 (end of wash out), week 12 (end of treatment 2))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-10-26
Completion: 2027-12-31
Eligibility
Age: 40 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: VA Office of Research and Development
Principal Investigators:
  • Isabella Soreca, MD (PRINCIPAL_INVESTIGATOR) - VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA
Contact Information
Study Contact:
Isabella Soreca, MD
(412) 688-6000
Isabella.Soreca@va.gov
L. A Pisarov
(412) 360-2251
Liubomir.Pisarov@va.gov
Isabella Soreca, MD
412-688-6000
Isabella.Soreca@va.gov
VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA
Interventions
  • Other: BLT — Bright light therapy delivered via glasses
  • Other: s-BLT — sham delivered with bright light therapy glasses to which a neutral density filter has been applied
Study Locations (1 sites)
VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh, Pennsylvania 15240 United States
Eligibility Criteria
Inclusion Criteria: * Documented diagnosis of OSA * Currently on CPAP or BiPAP for at least 3 months * with documented adherence (defined as wearing CPAP/BiPAP for \>6h/night on at least 75% of nights), and adequate control of sleep apnea, as indicated by an AHI of 10 or less when on CPAP * Excessive residual daytime sleepiness (Epworth score \> 10) * If taking alertness promoting medication, the investigators will require that they are on a stable dose for at least one month prior to entering the study and that they refrain from dose changes while participating in the study * If already prescribed BLT, subjects must not have used it for at least one month prior to participating Exclusion Criteria: * Shift work * Travel across time zones in the past month * Narcolepsy * Regular hypnotics use * Decompensated congestive heart failure (CHF) * Primary central sleep apnea, needing O2 therapy via nasal cannula * Poorly controlled diabetes (HgA1c\>8%) * Active substance use disorder * Dementia * Untreated bipolar disorder * the investigators will consider individuals with a diagnosis of bipolar disorder who are currently in treatment and stable * Macular degeneration, recent lasik surgery (within 3 months) * Legally blind * Taking medication that will cause photosensitivity to blue-green light spectrum wavelength * Already using bright light therapy
Conditions Suicidality, EEG, Suicidal Ideation, Nit...
Phase PHASE2
Enrollment 85
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

The primary aim of the NITOS study is to investigate the potential rapid antisuicidal effects of N2O in the transdiagnostic treatment of suicidal ideation. On day 1, patients will receive either nitrous oxide (50% N2O balanced with oxygen) or placebo (50% oxygen balanced with air). Seven days after the first inhalation, a second inhalation will be performed. All patients will receive N2O at least once during this trial. While the first inhalation will be double-blind, only the patients but not the raters will be blinded to the second inhalation (day 8). For mechanism of action and prediction, a nested biomarker substudy will employ multimodal techniques including analysis of hair and blood samples, and EEG.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: 50% N2O plus 50% O2 — Inhalation of 50% N2O plus 50% O2 for 45 min
  • Drug: Oxygen (O2) — 50% O2 plus 50% air for 45 min

Primary Outcomes

  • Beck Scale for Suicidal Ideation (BSS) (Day 0 to Day 2)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-01-13
Completion: 2026-09-30
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 85 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Zurich
Contact Information
Study Contact:
Angelina Frasch
0041583843666
angelina.frasch@pukzh.ch
Angelina Frasch
0041583843666
angelina.frasch@pukzh.ch
Psychiatric University Hospital Zurich
Interventions
  • Drug: 50% N2O plus 50% O2 — Inhalation of 50% N2O plus 50% O2 for 45 min
  • Drug: Oxygen (O2) — 50% O2 plus 50% air for 45 min
Study Locations (1 sites)
Psychiatric University Hospital Zurich, Zurich, 8032 Switzerland
Eligibility Criteria
Inclusion criteria: * Ability to give written informed consent * Moderate to severe suicidal ideation defined as a score ≥3 on the Montgomery-Asberg Depression Rating Scale (MADRS; Schmidtke et al., 1985) suicide item (item #10) as well as a self-report Beck Scale for Suicide Ideation (BSS; Kliem et al., 2017) items #4 plus #5 score ≥ 2 * Plasma homocysteine level ≤ 14 µmol/l Exclusion criteria: * Organic, including symptomatic, mental disorders (F00-F09; lifetime diagnosis) * Schizophrenia, schizotypal and delusional disorders (F20-F29; lifetime diagnosis) * Mental and behavioral disorders due to psychoactive substance use. Nicotine and cannabis will be ignored (F10-F19) * Non-medical (i.e., recreational) use of inhalational N2O during the last 12 months * Past intolerance or hypersensitivity to N2O * Critical illness * Severe cardiac disease * Pregnancy or breastfeeding * Pulmonary hypertension * Chronic cobalamin or folate deficiency unless treated with folic acid and/or vitamin B12 * History or evidence of any other medical or neurological condition that would expose the subject to an undue risk of a significant adverse event as determined by the clinical judgment of the investigator * Treatment with ketamine/esketamine during the last 4 weeks * Treatment with opioid medications during the last 3 months * Treatment with vagus nerve stimulation (VNS) or electroconvulsive therapy (ECT) within the last 3 months * Recent (within the last 4 weeks) or current use of benzodiazepines in excess of 5 mg lorazepam or equivalent per day * Finally, any other factors that, in the investigator's judgment, would unduly impact patient safety or compliance during the study.
Conditions Diabetes, Hypertension, High Cholesterol...
Phase NA
Enrollment 388
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

Socioeconomically disadvantaged populations with multiple chronic conditions have high rates of nonadherence to essential chronic disease medications after hospital discharge. Medication nonadherence after hospital discharge is significantly associated with increased mortality and higher rates of readmissions and costs among these patients. Major patient-reported barriers to essential medication use after hospital discharge among low-income individuals are related to social determinants of health (SDOH) and include: 1) financial barriers , 2) transportation barriers, and 3) system-level barriers. Although, medication therapy management services are important during care transitions, these services have not proven effective in improving medication adherence after hospital discharge, highlighting a critical need for innovative interventions. The Medication Affordability, Accessibility, and Availability in Care Transitions (Med AAAction) Study will test the effectiveness of a pharmacy-led care transitions intervention versus usual care through a pragmatic randomized controlled trial of 388 Medicaid and uninsured hospital in-patients with MCC from three large healthcare systems in Tennessee. The intervention will involve: 1) medications with zero copay, 2) bedside delivery then home delivery of medications, and 3) care coordination provided by certified pharmacy technicians/health coaches to assist with medication access, medication reconciliation, and rapid and ongoing primary care follow-up. We will examine the impact of the intervention during 12 months on 1) medication adherence (primary outcome) and 2) rapid primary care follow-up, 30-day readmissions, hospitalizations and emergency department visits, and costs. We will conduct key informant interviews to understand patient experience with the acre received during and after care transitions. By examining effectiveness of the intervention on outcomes including medication adherence, health care utilization, costs, and patient experience, this study will provide valuable results to health systems, payers, and policymakers to assist in future implementation and sustainability of the intervention for socioeconomically disadvantaged populations.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Other: Med AAAction intervention — The Med AAAction intervention will include the following components: 1) medications with zero copay, 2) bedside delivery and subsequent home delivery of medications, and 3) care coordination provided by certified pharmacy technicians/health coaches to assist with medication access, medication reconciliation, and rapid and ongoing primary care follow-up after hospital discharge. The intervention will be provided for one-year.

Primary Outcomes

  • Adherence to chronic disease medications (Adherence measured at 3, 6, 9, and 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-06
Completion: 2028-01-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 388 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Tennessee
Collaborators: Sponsor GmbH
Principal Investigators:
  • Satya Surbhi, PhD (PRINCIPAL_INVESTIGATOR) - UTHSC
Contact Information
Study Contact:
Satya Surbhi, PhD
646-438-0919
ssurbhi@uthsc.edu
Elizabeth A Tolley, PhD
901.422.6733
btolley@uthsc.edu
Shauntá M Chamberlin
865-305-5061
schamberlin@utmck.edu
University of Tennessee Medical Center
Interventions
  • Other: Med AAAction intervention — The Med AAAction intervention will include the following components: 1) medications with zero copay, 2) bedside delivery and subsequent home delivery of medications, and 3) care coordination provided by certified pharmacy technicians/health coaches to assist with medication access, medication reconciliation, and rapid and ongoing primary care follow-up after hospital discharge. The intervention will be provided for one-year.
Study Locations (2 sites)
University of Tennessee Medical Center, Knoxville, Tennessee 37920 United States
University of Tennessee Health Science Center/Regional One Health, Memphis, Tennessee 38103 United States
Eligibility Criteria
Inclusion Criteria: * Medicaid or uninsured inpatients * 21 years or older * ≥2 of the complex chronic conditions during index admission or prescribed/using ≥2 chronic medications for these conditions * Patients receiving chronic disease medications from the hospital pharmacy. * Patients will be eligible if they have multiple complex chronic conditions including diabetes, hypertension, high cholesterol, coronary artery disease, congestive heart failure, chronic lung disease, chronic kidney disease, arrhythmia, stroke, psychiatric disorders including depression and anxiety, or who are prescribed or using anticoagulants. Exclusion Criteria: * Medicare and Medicaid dual eligible patients. * If the primary reason for the index admission is related to cancer, pregnancy, or a surgical procedure for an acute problem * If patients have diagnoses of active psychosis, substance abuse, or suicidal ideation during the index admission. * If the planned discharge location is not home. * If patients are part of an existing pharmacy discharge program.
Conditions Psychosis, Mania, Depression
Phase NA
Enrollment 360
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-22
Study Details Design, interventions, and primary outcomes

About This Study

In West Africa, most people with serious mental illness receive care from traditional or faith healers at prayer camps. The stepped-wedge cluster randomized trial aims to evaluate the effectiveness of a dual-pronged intervention package comprised of a mobile health program designed to train healers to deliver evidence-based psychosocial interventions combined with pharmacotherapy delivered directly to the patients at their prayer camps via a visiting nurse in Ghana.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Crossover Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: mHealer — MHealer is a software application installed on smartphones that provides psychosocial treatment support and patient condition tracking.

Primary Outcomes

  • Psychiatric symptoms (Baseline, 4 weeks, 8 weeks)
  • Depressive symptoms (Baseline, 4 weeks, 8 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-10-25
Completion: 2027-05-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 360 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Washington
Collaborators: National Institute of Mental Health (NIMH)
Principal Investigators:
  • Dror Ben-Zeev, PhD (PRINCIPAL_INVESTIGATOR) - University of Washington
Contact Information
Study Contact:
Dror Ben-Zeev, PhD
206-685-9655
dbenzeev@uw.edu
Alexa Beaulieu, MPH
253-261-8661
beaulia@uw.edu
Angela Ofori-Atta, PhD
University of Ghana
Interventions
  • Behavioral: mHealer — MHealer is a software application installed on smartphones that provides psychosocial treatment support and patient condition tracking.
Study Locations (1 sites)
University of Ghana, Accra, GP4236 Ghana
Eligibility Criteria
Inclusion Criteria: * Aged 18 years or older * Speaks Twi or English * Current inpatient staying at a study prayer camp * A diagnosis of psychosis, mania, or depression Exclusion Criteria: * Serious physical illness or in need of urgent medical attention